patents

Recent Rosacea Blog Posts

While us in the rosacea world might consider products that are expensive while they are covered by exclusive patents, we are small fry in the drug market at large. Patents are due to shortly expire for Pfizer’s Liptor and Lilly’s Zyprexa. Lilly can expect a $3bn drop in revenue just from generic forms  of Zyprexa […]

Continue Reading

An update to the 2009 filing of the patent covering preparations of Ivermectin and Metronidazole has emerged at the USPTO Patent Application Site. That application was in turn a followup to the original French language application 0505918 from 2005. The patent covers many different combinations of ivermectin and metronidazole such as emulsion, cream, gel with […]

Continue Reading

Amneal Pharmaceuticals joins the Generic Oracea War

News today of yet another company in the courts fighting against Galderma for the right to make Generic Oracea. Amneal Pharmaceuticals, based in Gujarat, India, a producer of generic pharmaceuticals, has submitted an Abbreviated New Drug Application to the FDA. By doing so, Amneal Pharmaecuticals are seeking permission to market delayed release doxycycline 40mg for […]

Continue Reading

An unusual patent has surfaced that is suggesting the oral use of azelaic acid. Azelaic Acid is better known as the active ingredient in the topical finacea. This patent suggests an oral treatment that combines niacinamide with azelaic acid. The owner of the patent, Elorac is known from their recent trials of Carbamide Peroxide as […]

Continue Reading

An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan. As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011. MYLAN PHARMACEUTICALS INC., v.  GALDERMA LABORATORIES, L.P.; et. al. Mylan projected that Oracea’s […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.